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ABSTRAC T 
Thalassemia majo r (ß-thalassemia ) affect s a 
significant segmen t o f th e populatio n i n certai n 
areas o f th e world . Alteration s i n migratio n 
patterns hav e change d th e geographi c distribu -
tion o f thi s diseas e an d mad e i t a  worldwid e 
health problem . Ove r th e cours e o f th e pas t 2- 3 
decades hypertransfusio n therap y ha s signifi -
cantly increase d th e lif e expectancy , an d 
improved th e qualit y o f lif e o f thes e patients . A t 
the sam e tim e ther e ha s bee n a n increas e i n th e 
frequency o f complication s o f thi s therap y 
caused b y iro n overload . Endocrin e glan d 
abnormalitie s contribute d littl e t o th e morbidit y 
or mortalit y o f ß-thalassemi a i n th e past . A s a 
result o f hypertransfusio n therap y an d in -
creased longevity , however , endocrinopathie s 
have becom e mor e commo n an d contribut e 
significantly t o morbidit y i n thes e patients . I n 
this articl e w e briefl y revie w th e curren t under -
standing o f endocrin e glan d abnormalities , 
primarily cause d b y iro n overload , i n patient s 
with thalassemi a major . 
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INTRODUCTIO N 
Thalassemia majo r (ß-thalassemia ) first  describe d 
by Coole y an d Le e i n 192 5 i s a  hemoglobinopath y 
caused b y a  defec t i n th e productio n o f â  globulin . 
In homozygou s individual s th e severit y o f th e 
disease i s dependen t o n th e specifi c gene mutation
1
. 
The diseas e manifest s wit h anemi a an d hepato -
spelenomegaly an d i f no t treate d i s uniforml y fata l 
in childhood . Wit h periodi c bloo d transfusion s 
patients ar e relativel y asymptomati c an d lif e 
expectancy i s increased
2
. Th e standar d treatmen t a t 




. Th e endo -
crine glan d abnormalitie s currentl y see n i n thes e 
patients ar e primaril y cause d b y iro n overloa d 
and ar e potentiall y obviate d b y early , intensiv e 
chelation therapy . 
The tota l bod y iro n i n a  norma l adul t mal e i s 
3.5 g . I n hypertransfuse d patient s th e iro n loa d 
increases 200-25 0 m g fo r eac h uni t o f bloo d 
transfused. Thu s th e iro n burde n increase s rapidl y 
over t ime '
3
. I n thes e patient s th e usua l caus e o f 
death i s iro n overloa d tha t i s clinicall y an d 
pathologically identica l t o idiopathi c hemochromat -
osis. I n bot h condition s ther e i s hemosideri n 
deposition i n th e liver , spleen , heart , kidney , an d 
most endocrin e glands
4
. Ofte n ther e i s a  discrep -
ancy betwee n transfuse d iro n loa d an d th e degre e o f 
hemosiderosis . Advance s i n th e car e o f hematol -
ogical problem s hav e increase d th e lif e expectancy , 
but th e ris k o f secondar y endocrin e dysfunctio n 




. A  recen t 
study sugges t tha t 60 % o f patient s hav e hypo -
function of a t leas t on e endocrin e gland \ 
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SHOR T STATUR E 
Growth retardation , i n par t cause d b y anemi a 
and th e diversio n o f calori c resource s fo r erythro -
poiesis, i s frequentl y profound . Hypertransfusio n 
restores norma l growt h rates ; however , th e adoles -







Thus, eve n i n well-manage d patient s treate d wit h 
frequent transfusions and chelatio n therapy , norma l 
stature i s rarely attained . A t the presen t time growt h 
retardation an d delaye d o r absen t pubert y ar e th e 











. Patient s ar e usuall y ver y shor t (greate r 
than 2  standar d deviation s belo w th e mean ) 





Traditionally th e shor t statur e ha s been attribute d t o 
the chroni c hypoxi a associate d wit h sever e anemia . 
Patients wit h hemoglobi n concentratio n o f greate r 
than 1 0 g/d l gro w bette r tha n thos e wit h hemo -
globin level s of 5  g/dl an d th e rate of growth ca n b e 
increased b y hypertransfusion . Howeve r suc h treat -





Other potentia l cause s o f growt h impairmen t i n 
these patient s includ e delaye d puberty , lac k o f 







. Becaus e deferoxamin e chelate s zin c a s 
well a s iron , zin c deficienc y als o ma y b e a 





. Althoug h zin c i s involve d i n 
multiple physiologica l processe s tha t impac t linea r 
growth, i t i s no t clea r whic h on e o f thes e limit s 





Growth retardatio n ha s als o bee n attribute d t o 
growth hormon e deficienc y (GHD ) an d growt h 




. GH D secondar y 
to hypothalami c o r pituitar y damag e cause d b y iro n 
deposition, an d diminishe d productio n o f insulin -
like growt h factor- I (IGF-I ) b y th e live r resul t i n 




. Fastin g concentration s 
of G H a s wel l a s G H respons e t o provocativ e 









. Lo w seru m IGF- I concentration s 
and hig h o r norma l G H respons e t o stimulatio n 
tests hav e le d t o th e speculatio n tha t GHI S i s th e 
most likel y caus e o f growt h retardation
16
. Norma l 
or elevate d fastin g G H an d lo w IGF- I level s ar e 
thought t o b e th e resul t o f live r dysfunctio n 
secondary t o iro n depositio n an d hepatitis , causin g 
decreased degradatio n o f G H b y th e cirrhoti c liver , 




Chrysis et  al.  studie d th e GH-IGF-IG F bindin g 
protein (IGFBP ) axi s i n prepuberta l childre n wit h 
thalassemia an d norma l controls
19
. G H respons e t o 
provocative stimul i a s wel l a s IGF- I an d IGFBP- 3 
levels afte r a  4-da y cours e o f exogenou s G H wer e 
measured. The y foun d tha t lo w IGF- I an d IGFBP- 3 
concentrations ar e no t a  uniform findin g in childre n 
with thalassemia , bu t are frequentl y present i n those 
who hav e growt h retardation . I n thi s stud y IGF- I 
and IGFBP- 3 generatio n test s i n shor t childre n wit h 
thalassemia wer e simila r t o thos e foun d i n childre n 
with classi c GHD . Thes e finding s strongl y sugges t 
that growt h retardatio n i n thes e patient s i s cause d 
by disturbance s o f G H secretio n rathe r tha n G H 
insensitivity. Similarly , Rot h et  al.  reporte d lo w 
concentrations o f IGF- I an d IGFBP- 3 i n patient s 
with ß-thalassemia . I n thei r stud y patient s showe d 
an increas e i n bot h IGF- I an d IGFBP- 3 afte r 7 day s 
19 of exogenous G H . 
HYPOGONADIS M 
Delayed o r absen t pubert y an d attenuate d pub -
ertal growt h spur t ar e wel l documente d commo n 









. Developmen t o f secondar y sexua l 





. Breas t developmen t i s poo r an d patient s 
often hav e delaye d menarche , oligomenorrhe a o r 
secondary amenorrhea
25
. Boy s develo p spars e facia l 
and bod y hair . The y hav e decrease d libido , eve n i f 




. Th e caus e 
of delaye d pubert y appear s t o b e multifactorial ; 
however, ther e i s increasin g evidenc e that , i n 
patients wh o ar e maintaine d o n a n adequat e 
transfusion regimen , hypogonadis m i s primaril y 





Delayed pubert y an d hypogonadism , see n i n 
40-90% o f patients , ar e frequentl y cause d b y hypo -
1 c  Q  Q  0* 7 
gonadotropic hypogonadis m '  '  '  '  '  .  Gonado -
tropin respons e t o short - an d long-ter m stimulatio n 
with gonadotropi n hormon e releasin g hormon e 






. Th e presenc e o f hypo -
gonadotropic hypogonadis m i s furthe r supported b y 
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the histologica l findin g o f reduce d numbe r o f cell s 
in th e pituitar y glan d an d selectiv e iro n depositio n 






. Rasekh i et  al
29 
studied 3 6 patient s wit h thalassemi a an d foun d 
either a  smal l pituitar y glan d o r lo w pituitar y signa l 
intensity i n magneti c resonanc e image s i n 50 % o f 
patients. I n thi s stud y 78 % o f th e patient s ha d 
hypogonadotropic hypogonadism . Mea n pituitar y 
gland volum e i n thes e patient s wa s significantl y 
lower tha n i n thos e wh o di d no t hav e hypo -
gonadism. I n anothe r study , infusio n o f GnR H b y 
pump cause d gonada l enlargemen t an d uterin e 




Several report s hav e suggeste d tha t th e lac k o f 
sexual developmen t i n thalassemi a i s du e t o 




. Histologicall y ther e i s 
deposition o f iro n i n th e gonads . Autops y result s 
have als o show n interstitia l fibrosi s o f th e testes , 
small seminiferou s tubule s an d absenc e o f Leydi g 
cells. Ther e ar e als o report s o f hemosideri n 
deposition i n the ovary an d endometrium
4
. 
Although involvemen t o f th e pituitar y an d th e 
gonads i s variable , iro n depositio n appear s t o be th e 
primary caus e o f hypogonadis m i n mos t patients
1
. 
Initiation o f chelatio n therap y wit h deferoxamin e 
before pubert y ca n hel p patient s wit h transfusion -





. Bronspiegel-Weintro b et  al.  reporte d tha t 
90% o f childre n wh o wer e starte d o n chelatio n 
therapy an d maintaine d seru m ferriti n level s belo w 
2,000 ng/d l ha d undergon e spontaneou s pubert y 
9 year s later
26
. Patient s wh o hav e relativel y lo w 
ferritin concentration s an d thos e starte d o n chela -
tion therap y befor e ther e ar e significan t elevation s 
in seru m ferriti n hav e th e bes t prognosi s fo r 
spontaneous sexua l maturatio n an d norma l gonada l 
function
26
. Nonetheles s th e benefit s o f early , 
intensive therap y wit h deferoxamin e o n late r 
growth an d sexua l maturatio n mus t b e weighe d 
against th e reports o f deferoxamine-induce d growt h 







. Malabsorption , autoimmun e disorders , 
and zin c deficienc y ma y als o contribut e t o delaye d 
puberty an d gonada l failure
1
. 
Until th e 1970 s averag e lif e expectanc y fo r 
patients wit h thalassemi a majo r wa s onl y 15-2 0 
years an d i t was though t unlikel y tha t thes e patient s 
VOLUME 16 , NO. 7 , 200 3 
could eve r reproduce . No w wit h th e significan t 
improvement i n lif e expectancy , fertilit y ha s 





. Delaye d onse t o f menarche , 
amenorrhea, anovulatio n an d infertilit y continu e t o 
be common . Howeve r intensiv e therap y wit h bloo d 
transfusions an d deferoxamine , a s wel l a s 
appropriate us e o f medication s t o induc e ovulation , 
37 38 
have mad e successfu l pregnancie s possibl e '  . 
Although som e patient s hav e ovaria n failure , 
anovulation i s primaril y th e resul t o f hypogonado -
tropic hypogonadism . Severa l report s o f spontane -
ous conceptio n indicat e tha t anovulatio n i s no t 
inevitable. Conceptio n followin g inductio n o f 




. Risk s o f feta l 
complications includin g growt h retardatio n an d 
pre-term labo r ar e hig h an d ar e attribute d t o feta l 
hypoxia
39
. Frequen t bloo d transfusio n t o kee p th e 
maternal hemoglobi n concentratio n ove r 1 0 g/d l 
during gestatio n ma y decreas e th e ris k t o th e 
HYPOPARATHYROIDIS M i f 
Hypoparathyroidism secondar y t o siderosis , first 
described b y Gabriel e i n 1971
41
, i s relativel y 
common; however , th e incidenc e o f th e disorde r 







Intracranial calcification s cause d b y hypopara -
thyroidism ha s als o bee n reported
43
. Hypopara -
thyroidism i s no w a  well-recognize d complicatio n 
of bloo d transfusio n therap y an d i s cause d b y 
deposition o f iro n i n th e parathyroi d glands
44
. 
Asymptomatic hypocalcemi a i s commo n i n thes e 
patients an d ma y b e misse d fo r som e time . Thu s i t 
is importan t t o loo k fo r mil d hypoparathyroidis m 
and hypocalcemi a beginnin g i n th e secon d decad e 
of life . Improvement s i n chelatio n therap y hav e 
resulted i n a  reductio n o f hypoparathyroidism . 
However i t i s clea r tha t optima l chelatio n therap y 






It i s no t know n wh y som e patient s wit h thalas -
semia develo p hypoparathyroidis m whil e other s d o 
not. I n som e studie s patient s wit h hig h level s o f 
serum ferriti n ha d a  highe r incidenc e o f hypo -
parathyroidism, whil e othe r investigator s hav e bee n 
unable t o sho w suc h a  correlation
44 45
. A  numbe r o f 
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mechanisms hav e bee n postulate d fo r the glandula r 
damage cause d b y iro n overload , includin g fre e 




Reduced bon e mass , fractures , an d pain , 
independent o f parathyroi d abnormalities , ar e 
common cause s o f morbidit y an d disabilit y i n 
homozygous ß-thalassemia . Iro n overload , hypo -
gonadotropic hypogonadism , expansio n o f bon e 
marrow wit h cortica l thinning , an d deleteriou s 
effects o f chelatin g agent s o n osteoblast s hav e al l 





Reduced bon e minera l densit y (BMD ) i s a 




. I n a  longit -
udinal stud y o f 1 2 adult s wit h thalassemi a major , 
Pollak et  al.  foun d continue d bon e los s over tim e i n 
those wh o ha d hypogonadism
46
. I n thi s study , 75 % 
of patient s ha d lo w IGF- I an d ther e wa s a 
correlation betwee n seru m IGF- I concentration s 
and spin e an d hi p BMD . IGF- I i s a  regulato r o f 
osteoblast differentiatio n an d proliferation , a s wel l 
as a  stimulato r o f osteoclas t activatio n an d forma -
tion. Thu s i t ma y ac t a s a  couplin g agen t i n th e 






. Currently , n o 
specific therap y i s available . Ne w therapeuti c 
modalities, suc h a s bisphosphonate s an d specifi c 
estrogen recepto r modulators , hav e brough t abou t 




. However , lon g 
term outcom e i n optimall y treate d patient s i s no t 
yet known . 
Vitamin D  deficienc y a s wel l a s over t 
osteomalacia an d ricket s see n i n ß-thalassemi a 
have previousl y bee n attribute d t o defectiv e 
25-hydroxylation o f vitami n D  i n th e liver , a s see n 
in patient s wit h hemochromatosis
52
. However , 
presence o f abnorma l calciu m metabolis m despit e 
treatment wit h effectiv e chelatin g agent s suggest s 
that additiona l vitami n D  abnormalitie s ma y b e 
present. Rickets-lik e bon y lesions , gen u valgum , 
and metaphysea l change s resultin g i n a  dis -
proportionately shor t trun k als o hav e bee n attribut -





D I A B E T E S M E L L I T U S 
Abnormal carbohydrat e metabolis m i s fre -
quently see n i n patient s wit h thalassemia
54
. Glucos e 
intolerance usuall y develop s durin g th e secon d 
decade o f life , eve n thoug h baselin e bloo d suga r 
levels ar e frequentl y normal . Thi s abnormality , 
early i n th e cours e o f th e disease , appear s t o b e 
related mor e t o insuli n resistanc e tha n t o decrease d 
insulin production
55
. Th e latte r complicatio n 





Glucose intoleranc e an d diabete s mellitu s ar e 








. Th e incidenc e 
correlates wit h seru m ferriti n levels . Othe r ris k 
factors includ e age , stag e o f puberty , frequenc y o f 
blood transfusion , iro n chelatio n therapy , famil y 





Diabetes mellitu s ha s bee n observe d t o develo p 
shortly afte r a n episod e o f acut e vira l hepatitis . 
Chronic hepatiti s i s als o though t t o hav e a  diabeto -
genic effect
59
. Hepati c dysfunctio n appear s t o b e a 







. Therefor e test s fo r 
early identificatio n shoul d b e a n integra l par t o f 
long-term follow-u p of patients olde r than 1 0 years. 
Iron depositio n i n th e pancrea s ha s bee n wel l 
documented histologically . Thu s relativ e insuli n 




, bu t th e mai n caus e 




. Iro n depositio n 
in th e live r ma y potentiall y interfer e wit h sup -
pression o f hepati c glucos e productio n b y insulin
58
. 
In addition , muscl e damag e cause d b y iro n deposit s 





Even thoug h insuli n concentration s ma y b e 
normal o r elevated , insuli n resistanc e result s i n th e 
development o f diabete s mellitus . Glyburid e ha s 
been reporte d t o provide a  means o f postponing thi s 




. Whethe r th e 
newer ora l hypoglycemi c agent s tha t increas e 
insulin sensitivit y i n tissue s hav e a  beneficia l long -
term effec t in these patient s i s yet to be studied . 
H Y P O T H Y R O I D I S M 
Patients wit h ß-thalassemi a ma y develo p hypo -
thyroidism afte r th e firs t decad e o f life . Th e 






. Thyroi d functio n 
tests variabl y sho w norma l function , primar y o r 









. Althoug h som e patient s hav e thyroi d 
autoantibodies, immun e mediate d hypothyroidis m 
is uncommon . Histologicall y hemosiderosi s o f th e 
thyroid glan d ha s bee n documented . Thi s complica -
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tion i s associate d wit h hig h frequenc y o f trans -
fusions, iro n load , an d othe r evidenc e o f iro n 
toxicity, includin g growt h failure
4,65
. Centra l hypo -
thyroidism i s very rare
66
. 
The 'lo w T 3 syndrome ' ha s bee n describe d i n 
adults an d childre n wit h chroni c non-thyroida l 
disease. I n thalassemia , th e presenc e o f chroni c 
liver abnormalitie s o r th e basi c diseas e itsel f ca n 





Because thalassemi a i s a  chroni c disease , non -
specific symptom s o f hypothyroidis m ma y no t b e 
recognized. Therefore , periodi c assessmen t o f 
thyroid functio n i s warranted . Patient s wit h over t 
hypothyroidism an d symptomati c patient s clearl y 
should b e treated , bu t treatmen t o f clinicall y 
euthyroid patient s wit h mil d compensate d hypo -
thyroidism i s controversial
65
. 
ADRENAL INSUFFICIENC Y 
Adrenal failur e i s relativel y uncommon . I n a 
recent repor t prevalenc e o f adrena l abnormalitie s 
was 13% . Althoug h ther e i s depositio n o f iro n i n 
the pituitary , adrena l underactivit y appear s t o b e 
caused b y primar y adrena l failur e cause d b y iro n 
overload. Th e affecte d patient s hav e a  hig h concen -
tration o f adrenocorticotropi c hormon e (ACTH ) 




Widespread populatio n screenin g an d prenata l 
diagnosis ha s decrease d th e numbe r o f patient s wit h 
ß-thalassemia i n som e communities . A t th e sam e 
time, becaus e o f increase d immigratio n fro m 
endemic areas , th e numbe r o f patient s i n Europ e 
and Nort h Americ a ha s increased . Althoug h bon e 
marrow/stem cel l transplantatio n ma y offe r hop e 
for cur e i n th e future , th e curren t recommende d 
treatment i s a  combinatio n o f hypertransfusio n an d 
iron chelation . Hypertransfusio n alon e ha s improve d 
life expectanc y fo r patient s wit h thalassemi a major . 
Chelation therapy , whic h i s burdensom e an d 
expensive, i s ofte n no t availabl e i n man y area s o f 
TABLE 1 
Recommende d endocrin e studie s i n patient s wit h thalassemi a afte r th e ag e o f 1 0 year s 
1. T
4
, T 3 uptake , TS H 
2. Fastin g glucose , insulin , an d hemoglobi n A
! c
* 
3. Rando m GH , IGF-I , an d IGFBP- 3 * * 
4. Calcium , phosphorus , an d plasm a protein s 
5. Parathyroi d hormone , 25-OHD , an d 1,25-OH D (i f C a o r Ñ i s abnormal ) 
6 . M o r n i n g Cort iso l a n d A C T H 
7. Seru m electrolyte s 
8. LH , FSH , an d estradiol/testosteron e (afte r ag e 1 2 years ) 
9. Bon e ag e (i f growt h rat e i s no t optimal ) 
10. Bon e densit y (afte r ag e 1 4 years ) 
* O r ora l glucos e toleranc e test . 
** Conside r provocat iv e tests . 
T
4
 =  thyroxine ; TS H =  thyroi d st imulat in g hormone ; G H =  growt h hormone ; 
IGF-I =  insulin-lik e growt h factor-I ; IGFBP- 3 =  insulin-lik e growt h facto r b indin g protein-3 ; 
2 5 - O H D =  25-hydroxycholecalc i ferol ; 1 ,25-OH D =  1,25-dihydroxycholecalciferol ; 
A C T H =  adrenocort icotropi c hormone ; L H =  luteinizin g hormone ; 
FSH =  follicl e st imulatin g hormone . 
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the world , an d complianc e ma y b e suboptimal . 
Thus, endocrin e abnormalities , primaril y cause d b y 
iron overload , ar e seen with increasin g frequency . 
Virtually al l endocrin e gland s ca n b e affecte d by 
iron toxicity . I n younge r asymptomati c patient s 
careful height an d weigh t measurement s ever y 6-1 2 
months shoul d b e made . I f growt h rat e an d weigh t 
gain ar e adequate , endocrin e studie s nee d no t b e 
done. I n vie w o f th e frequenc y o f endocrin e glan d 
failure i n olde r patients , however , w e recommen d 
annual screenin g test s afte r th e ag e o f 1 0 year s 
(Table 1) . Provocativ e test s fo r G H shoul d als o b e 
carried ou t i f growth rat e i s inadequate . 
GH therap y i s expensiv e an d ma y no t b e 
available. However , i f ther e i s n o clea r reaso n fo r 
growth failure , we conside r a  therapeuti c tria l eve n 
if tes t result s ar e normal . I n vie w o f th e beneficia l 
effects o f gonada l steroid s o n bon e an d th e 
potential advers e psychologica l impac t o f delaye d 
puberty, w e als o recommen d treatmen t wit h smal l 
doses of estrogens/androgen s i f there i s no evidenc e 
of spontaneou s pubert y b y th e ag e o f 1 4 year s i n 
girls an d 1 5 year s i n boys . Treatmen t o f th e 
endocrinopathy associate d wit h thalassemi a shoul d 
be undertake n a s soo n a s th e diagnosi s i s 
established. Earl y recognitio n an d treatmen t wil l 
decrease th e morbidit y associate d wit h endocrin e 
gland failur e and enhanc e the qualit y o f life in thes e 
patients. 
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